EUVIMEDEUVIMED entdecken
Crossref

Long‐term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges

Jiangyuan Zhou, Yanan Li, Tong Qiu, Xue Gong, Kaiying Yang, Xuepeng Zhang, Zixin Zhang, Yuru Lan, Fan Hu, Qiang Peng, Yongbo Zhang, Feiteng Kong und 2 weitere

International Journal of Cancer · 2023-08 · 153 (3) · 600-608

DOI: 10.1002/ijc.34509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 22.03.2023. Verfasst von Jiangyuan Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Kasabach-Merritt Syndrome, Hemangioendothelioma, Sarcoma, Kaposi. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: 1·3·5 Project for Disciplines of Excellence Clinical Research Incubation Project, West China Hospital of Sichuan University, Key Project in the Science & Technology Program of Sichuan Province, Med-X Center for Informatics Funding Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with sirolimus, an inhibitor of the mammalian target of rapamycin pathway, has improved the prognosis of patients with kaposiform hemangioendothelioma (KHE). However, the efficacy, durability and tolerability of long‐term sirolimus treatment in patients with KHE have not been well elucidated. We performed efficacy and safety assessments based on more than 4.5 years of follow‐up in patients receiving sirolimus therapy for KHE. One hundred sixty‐seven patients were analyzed, including 102 (61.1%) patients with the Kasabach‐Merritt phenomenon (KMP). Follow‐up was conducted after a median of 56.0 months. A total of 154 (92.2%) patients had a durable response to sirolimus treatment. No difference in durable response was found between patients without KMP and patients with KMP (95.4% vs 90.2%; difference, 5.2%; 95% confidence interval [CI], −4.0% to 13.1%). Rebound growth occurred in 17.3% of patients upon sirolimus discontinuation. Early treatment discontinuation (odds ratio [OR]: 3.103; 95% CI: 1.529‐6.299; P = .002) and mixed lesion type (OR: 2.271; 95% CI: 0.901‐5.727; P = .047) were associated with tumor rebound growth. No KHE‐related deaths occurred in this cohort. At the last follow‐up, approximately 17.4% of patients had active disease and/or changes in body structures to a variable extent. Serious adverse events occurred most commonly during the first year of sirolimus therapy. Follow‐up of almost 4.5 years demonstrated that the efficacy of sirolimus persisted over time and that long‐term treatment with sirolimus was not associated with unacceptable cumulative toxicities. However, nonresponse, tumor relapse and long‐term sequelae remained challenges despite intensified and prolonged sirolimus therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kasabach-Merritt SyndromeHemangioendotheliomaSarcoma, KaposiHumansSirolimus

Stichwörter der Autor:innen

Kasabach-Merritt phenomenonkaposiform hemangioendotheliomalong-termsirolimustreatment

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Vascular & Interventional Radiology, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Department of Pediatric Surgery, Chengdu Women and Children's Central Hospital, Chengdu, China.
  • Department of Pediatric Surgery, Sichuan Women and Children's Hospital, Chengdu, China.
  • Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.

ORCID-Profile: Yi Ji

Förderung

  • 1·3·5 Project for Disciplines of Excellence Clinical Research Incubation Project, West China Hospital of Sichuan University
  • Key Project in the Science & Technology Program of Sichuan Province
  • Med-X Center for Informatics Funding Project
  • National Natural Science Foundation of China
  • Project of '0 to 1' of Sichuan University

Zitieren

APA

Zhou, J., Li, Y., Qiu, T., Gong, X., Yang, K., Zhang, X., Zhang, Z., Lan, Y., Hu, F., Peng, Q., Zhang, Y., Kong, F., Chen, S., & Ji, Y. (2023). Long‐term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges. International Journal of Cancer, 153(3), 600-608. https://doi.org/10.1002/ijc.34509

Vancouver

Zhou J, Li Y, Qiu T, Gong X, Yang K, Zhang X, et al. Long‐term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges. International Journal of Cancer. 2023;153(3):600-608. doi:10.1002/ijc.34509

BibTeX
@article{Zhou2023,
  author = {Zhou, Jiangyuan and Li, Yanan and Qiu, Tong and Gong, Xue and Yang, Kaiying and Zhang, Xuepeng and Zhang, Zixin and Lan, Yuru and Hu, Fan and Peng, Qiang and Zhang, Yongbo and Kong, Feiteng and Chen, Siyuan and Ji, Yi},
  title = {Long‐term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {153},
  number = {3},
  pages = {600--608},
  doi = {10.1002/ijc.34509}
}
Kostenlos starten →